Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin

Highlights • S100A7 production is increased under inflammatory contexts, such as in psoriasis. • Adalimumab, etanercept or ustekinumab downregulate S100A7 to a different extent. • Limiting the action of S100A7 may represent a therapeutic approach for psoriasis.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of dermatological science 2015-10, Vol.80 (1), p.38-44
Hauptverfasser:	D’Amico, Fabio, Trovato, Chiara, Skarmoutsou, Evangelia, Rossi, Giulio A, Granata, Mariagrazia, Longo, Valentina, Gangemi, Pietro, Pettinato, Maurizio, Mazzarino, Maria Clorinda
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - pharmacology Adalimumab - therapeutic use Adult Aged Biological therapy Dermatology Etanercept - pharmacology Etanercept - therapeutic use Female Humans IL-12/-23p40 Immunohistochemistry Male Middle Aged Psoriasin Psoriasis Psoriasis - drug therapy Psoriasis - metabolism S100 Calcium Binding Protein A7 S100 Proteins - metabolism S100A7 Skin - drug effects Skin - metabolism TNF Ustekinumab - pharmacology Ustekinumab - therapeutic use Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • S100A7 production is increased under inflammatory contexts, such as in psoriasis. • Adalimumab, etanercept or ustekinumab downregulate S100A7 to a different extent. • Limiting the action of S100A7 may represent a therapeutic approach for psoriasis.
ISSN:	0923-1811 1873-569X
DOI:	10.1016/j.jdermsci.2015.07.009